Edwards Lifesciences Sees Unusually High Options Volume (NYSE:EW)

Edwards Lifesciences Corporation (NYSE:EW) saw some unusual options trading on Monday. Stock traders acquired 2,518 call options on the company. This is an increase of approximately 93% compared to the typical volume of 1,303 call options.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on EW. Wall Street Zen upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Saturday. TD Cowen reissued a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Leerink Partners upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and raised their price target for the company from $87.00 to $101.00 in a report on Friday, July 24th. Mizuho lifted their price target on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. Finally, BTIG Research reiterated a “buy” rating and issued a $110.00 price target on shares of Edwards Lifesciences in a research note on Friday. Seventeen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences has an average rating of “Moderate Buy” and a consensus target price of $100.27.

Edwards Lifesciences Trading Up 1.4%

Shares of Edwards Lifesciences stock opened at $85.58 on Tuesday. Edwards Lifesciences has a twelve month low of $72.30 and a twelve month high of $96.29. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The business has a 50-day moving average price of $88.97 and a 200-day moving average price of $85.84. The firm has a market cap of $49.27 billion, a price-to-earnings ratio of 49.18, a PEG ratio of 2.21 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.04. The business had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities research analysts anticipate that Edwards Lifesciences will post 3 EPS for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other news, VP Annette Brüls sold 2,644 shares of the stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $89.98, for a total transaction of $237,907.12. Following the completion of the sale, the vice president directly owned 17,984 shares in the company, valued at approximately $1,618,200.32. This represents a 12.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $87.51, for a total value of $54,168.69. Following the transaction, the vice president directly owned 40,034 shares in the company, valued at $3,503,375.34. This trade represents a 1.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 5,664 shares of company stock worth $511,918 in the last ninety days. 0.31% of the stock is owned by company insiders.

Institutional Investors Weigh In On Edwards Lifesciences

Hedge funds have recently added to or reduced their stakes in the business. California State Teachers Retirement System increased its holdings in shares of Edwards Lifesciences by 9,187.8% during the 2nd quarter. California State Teachers Retirement System now owns 80,962,062 shares of the medical research company’s stock worth $7,323,828,000 after buying an additional 80,090,362 shares during the last quarter. BlackRock Inc. acquired a new position in Edwards Lifesciences in the second quarter valued at approximately $5,318,092,000. Bank of New York Mellon Corp purchased a new position in Edwards Lifesciences in the second quarter worth approximately $1,274,082,000. Norges Bank acquired a new stake in Edwards Lifesciences during the fourth quarter worth $803,686,000. Finally, Bank of America Corp DE acquired a new stake in Edwards Lifesciences during the second quarter worth $605,397,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders.

The company’s portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products.